SCHEMBL2441287

SCHEMBL2441287

O=C(Nc1noc2cccc(OCC(F)(F)F)c12)c1ccccc1Br

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.43
TP53 P04637 3/20 0.43
F2R P25116 1/20 0.43
LCLAT1 Q6UWP7 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
UGCG Q16739 1/20 0.40
MRGPRX1 Q96LB2 2/20 0.40
RXFP1 Q9HBX9 2/20 0.39
SGMS1 Q86VZ5 1/20 0.38
SGMS2 Q8NHU3 1/20 0.38
AURKB Q96GD4 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437982 0.88 S1PR1 (0.49) SMN1; SMN2TP53LCLAT1UGCGRXFP1
SCHEMBL2439122 0.85 UGCG (0.43) SMN1; SMN2TP53LCLAT1UGCGMRGPRX1
SCHEMBL2441155 0.83 UGCG (0.41) SMN1; SMN2TP53LCLAT1UGCGMRGPRX1
SCHEMBL2440435 0.82 LCLAT1 (0.43) SMN1; SMN2TP53LCLAT1UGCGMRGPRX1
SCHEMBL2439200 0.81 PYGL (0.43) SMN1; SMN2TP53LCLAT1MRGPRX1SGMS1
Cyclohexane SCHEMBL2442882 0.80 KCNA5 (0.39) SMN1; SMN2TP53LCLAT1UGCGSGMS1
Cyclopropane SCHEMBL2441865 0.80 KCNA5 (0.39) SMN1; SMN2TP53LCLAT1UGCGSGMS1
SCHEMBL2438849 0.80 SMN1; SMN2 (0.45) SMN1; SMN2TP53L3MBTL1UGCGNPC1
SCHEMBL2440764 0.79 TP53 (0.44) SMN1; SMN2TP53LCLAT1UGCGSGMS2
SCHEMBL2438284 0.79 KCNQ3 (0.46) SMN1; SMN2TP53LCLAT1UGCGSGMS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 SMN1; SMN2 2423/4885TP53 4882/4885F2R 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.